Quantum Stocks Split: Suppliers Rise While Pure‑Play Makers Slip

On September 9, 2026 the quantum‑computing corner of the market behaved less like a single herd and more like a group of strangers passing each other on a sidewalk. FormFactor jumped about 4½ % to $114.72, while IonQ slid nearly 4 % to $38.92 and D‑Wave drifted down 1.25 %.

It wasn’t just a random wobble. The broader indices were all a shade lower – the S&P 500 off 0.56 %, the Nasdaq 100 down 0.47 % and the Dow losing 0.80 % – so the quantum‑related moves were larger than the market drag and, crucially, they went in opposite directions.

Why does this matter? For most of the sector’s brief history the stocks moved together because they were all priced on the same distant promise: a machine that uses quantum bits – qubits – to solve problems classical computers can’t. That promise is still there, but investors are starting to tease apart two very different business models.

Pasqal (PSQL) sits closest to the original “pure‑play” idea. With a share price hovering around $8, it’s still mostly an option on future breakthroughs rather than a cash‑generating operation. Its low price and scant coverage reflect that status.

FormFactor (FORM) is a semiconductor‑test supplier. Its probe cards and cryogenic test rigs let chip makers validate both traditional and quantum devices before they ever hit a lab bench. The demand for those tools exists regardless of which quantum architecture wins the race.

Keysight Technologies (KEYS) provides a broader suite of test and measurement gear used in research labs, defence programmes and commercial development. Quantum is just one line in a much larger catalog, so the company’s fortunes are less tied to the success of any single qubit approach.

This structural split explains the risk differences. A supplier gets paid today for the experiments it supports, whereas a pure‑play only gets rewarded if the experiment eventually works – a payoff that may be years away.

That’s not to say IonQ and D‑Wave have become irrelevant. They remain the go‑to names for most retail investors hearing a quantum headline, and both slipped lower on the same day that a supplier climbed. The drop in pure‑play shares simply signals a cooling of appetite for long‑duration, pre‑revenue bets, not a collapse in demand for test equipment.

What should investors watch next? Three things stand out:

• Interest‑rate environment: Companies whose cash flows are far in the future – like pure‑play quantum firms – are ultra‑sensitive to changes in discount rates. A market that’s higher‑for‑long can keep pressure on those stocks.
• Revenue disclosure: Right now, FormFactor and Keysight don’t break out quantum‑related sales, because the numbers are still modest. If they start reporting a distinct quantum line, the valuation gap with pure plays could widen or shrink dramatically.
• Capital needs: Pasqal’s low share price reflects the market’s demand for proof before it pays a premium. Should the sentiment toward pure‑play stocks stay muted, funding for early‑stage quantum firms could become more expensive.

In short, a one‑day divergence isn’t a trend, but it does hint that the theme is evolving. When investors begin to separate the builders of the quantum machine from the folks who test it, the conversation shifts from lofty narrative to real‑world revenue streams.

All price points quoted are intraday as of the last trade at 16:28 GMT on September 9, 2026.